Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cellskill is a regenerative medicine platform and service developed by the Bioscience Institute. It focuses on the use of autologous stem cells and exosomes for anti-aging and regenerative therapies. The platform involves the extraction, expansion, and cryopreservation of a patient's own cells—typically adipose-derived stem cells—which are then re-administered to promote tissue repair, skin rejuvenation, and systemic anti-aging effects. By leveraging the paracrine signaling of stem cells and the bioactive cargo of exosomes, Cellskill aims to modulate the cellular microenvironment and stimulate endogenous healing processes to treat aging-related decline and other degenerative conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cellskill.